Cullinan Therapeutics, Inc. (CGEM)
(Delayed Data from NSDQ)
$7.88 USD
-0.20 (-2.48%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $7.89 +0.01 (0.13%) 4:42 PM ET
4-Sell of 5 4
F Value C Growth A Momentum D VGM
Fundamental Charts
About Dividend Yield (TTM)
Cullinan Therapeutics, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
CGEM 7.88 -0.20(-2.48%)
Will CGEM be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CGEM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CGEM
Wall Street Analysts Predict a 292.51% Upside in Cullinan Therapeutics (CGEM): Here's What You Should Know
CGEM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for CGEM
Cullinan Therapeutics management to meet virtually with Clear Street
Cullinan Therapeutics management to meet virtually with Clear Street
Upcoming Virtual Meeting for Cogent Biosciences (CGEM) Investors
Taiho Oncology and Cullinan Therapeutics Announce Acceptance of Abstracts for Zipalertinib at ...
Cullinan Therapeutics: Betting On Zipalertinib NDA Catalyst